To study the repertoire and specificity of T lymphocytes infiltrating skin lesions during graft-versus-host disease (GVHD), we performed an exhaustive molecular and functional analysis of 146 T-cell clones derived from the skin of three patients undergoing an acute GVHD after allogeneic bone marrow transplantation (BMT) from HLA-mismatched related donors. Analysis of T-cell receptor (TCR) rearrangement and TCR chain junctional sequences demonstrated the presence of 11 distinct clones among the 64 derived from patient UPN1, six among the 58 derived from patient UPN2, and seven among the 24 derived from patient UPN3. Three of the 11 T-cell clones from patient UPN1, and all clones from patients UPN2 and UPN3 reacted with mis-
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LLOGENEIC BONE MARROW transplantation (BMT)
is an important therapeutic option that can cure certain malignant and nonmalignant diseases. Its chief complication, the acute graft-versus-host disease (GVHD),' is caused by T lymphocytes and is indissociable from the beneficial antileukemic reaction known as the graft versus leukemia (GVL) effect, which is also mediated by T cells. Accordingly, efforts to eliminate GVHD through T-cell depletion have led to increased relapses, the overall picture of depletion being negative.' a0 T lymphocytes, the main effectors of the allogeneic reaction, possess antigenic receptors whose variable regions are made up of a combination of different T-cell receptor (TCR)-V, -D and -J elements (VDJ for 0 chains and VJ for a chains). Besides this combinatorial diversity, a junctional diversity is produced by the addition or removal of nucleotides at the junctions of the rearranged genes. Combinatorial and junctional diversity of T-cell receptors are now both amenable to analysis: the former by using TCR-V region specific monoclonal antibodies (MoAbs) and the latter by studying CDR3 length using recently developed technique^.'.^ Determining the T-cell response diversity in GVHD is particularly crucial as, if a restricted T-cell repertoire is involved, this repertoire could be specifically removed.5 This would permit specific therapy with less global immunosuppression.
The two major observations in favor of such a possibility are the following: (1) acute GVHD occurs very rapidly after BMT, at a time when T-cell reconstitution is just starting. Indeed, numerous T-cell repertoire alterations have recently been documented during this period, demonstrating that a few T-cell clones can represent an important proportion of the T-cell pool at the time GVHD occurs.69 (2) The main immunological characteristic of GVHD is its tissue specificity. This might lead to an even more restricted response as T cells can distinguish between major histocompatibility complex (MHC) molecules on different cell types.'@'* To determine whether or not the T-cell response is restricted during acute GVHD, we first developed a method to isolate in vivo activated T cells from the skin. Next, we characterized both the diversity of the HLA-target antigens recognized during the GVHD process by these T cells and the diversity of their TCR. A total of 146 T-cell clones derived from four skin biopsies performed on three patients at the onset of I (HLA-A2 and -B271 and  class II (HLA DP101, DP401, DP1301, DQ8 , and DR402) molecules were recognized during this early antihost response.
Finally, both TCR a and p chains turned out to be extremely diverse, even within populations of clones derived from the same patient and directed against the same HLA allele. Taken together, these results indicate that any HLA mismatch is potentially targeted during early GVHD, and that the T-cell response at the onset of GVHD is both oligoclonal and highly diversified. 0 7 9 9 6 by The American Society of Hematology.
acute GVHD were studied. The results obtained support the view that activated T cells infiltrating the skin at the onset of GVHD are host specific and can recognize any HLA mismatch between donor and recipient. Moreover, this Tcell response appears at the same time oligoclonal and is highly diverse in terms of TCRV usage.
MATERIALS AND METHODS
Patients. Four biopsies were obtained from three patients.
Patient UPNl. A 9-year-old boy was grafted for chronic myelogenous leukemia with his mother's bone marrow. HLA typing is indicated in Table 1 . The conditioning regimen consisted of cyclophosphamide (120 mgkg) and total body irradiation (TBI): 12 Gy through six fractions. GVHD prophylaxis consisted of cyclosporine A (CsA) and methotrexate (at days 1, 3, 6, and 11) and 5 mg/day of BB10, an anti-interleukin (IL-2R) antibody, for 10 days. GVHD was first suspected at day 13, but the first skin biopsy culture was negative. At day 34, GVHD was again suspected, and three skin biopsies were performed for histological study, immunochemistry, and culture. A large infiltrate was observed composed of 70% CD8' and 5% CD4+ T cells; no CD1 Langerhans cells were detected. Keratinocytes expressed class II. Biopsy-confirmed GVHD was treated with CsA (3 mgkg/d), corticosteroids (2 mgkg/d), and BBlO. Unfortunately, treatment failed and GVHD extended to gut and liver. The patient died at day 99 postgrafting.
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GASCHET AL Patient UPNZ. A 7-year old boy was grafted with his mother's bone marrow for acute lymphoblastic leukemia in second complete response. HLA typing is indicated in Table 1 . The conditioning regimen consisted of T B 1 and high doses of cytarabine and melphaIan. GVHD prophylaxis consisted of T-cell depletion of the graft using anti-CD2 and anti-CD7 MoAbs with baby rabbit complement. In addition, the patient received intravenously (W) anti-LFA-1 and anti-CD2 MoAbs at a dose of 0.2 mg/kg/d from day -3 to day 10 and from day -2 to day 11, respectively. Skin lesion occurred on day 19, and three skin biopsies for histological study, immunochemistry, and culture were performed on day 22 (biopsy UPN2-a). Because the clinical aspect was compatible with acute GVHD, treatment with cyclosporine (3 mg/Kg/d IV) and steroids (2 mg/kg/d IV) was started on day 23 and continued although histological and immunological aspects were only weakly consistent with GVHD. Despite this treatment, skin lesions flared, and a second skin biopsy was performed on day 27 (biopsy UPN2-b). At that time GVHD was histologically evident. Treatment of GVHD was then modified with IV addition of MoAbs anti-L-2R (BBIO)l3 (5 mg/d from day 29 to day 39 then 2.5 mg/d every other day until day 80) and antitumor necrosis factor (TNF) a! (5 mg/d from day 29 to day 32). GVHD completely disappeared, and no chronic GVHD was documented, but on day 120, a hematological relapse was documented and the patient died. MoAbs for T-cell depletion or IV use were provided by P. HervC from the Centre de Transfusion Sanguine de BeSancon, France.
Patient UPN3.
A 10-year old boy with idiopathic myelodysplasia and severe pancytopenia with, at the time of transplant, a 7 year history of transfusion (red blood cells and platelets). The conditioning regimen consisted of T B 1 12 Gy, high-dose cytarabine and melphalan (idem as for patient UPN2). GVHD prophylaxis was exactly the same as for the previous patient. The donor was his mother. The patient failed to engraft, as on day 40 bone marrow aspiration showed no cells, and analysis of DNA in marrow and peripheral blood cells by fingerprinting showed no donor DNA. The patient received a second conditioning regimen consisting of busulfan 8 mg/kg over 2 days and cyclophosphamide 200 m a g over 4 days. The marrow of the father was harvested and T-cell depleted with MoAbs (anti-CD2, anti-CD7 plus baby rabbit complement). Additional in vivo immunotherapy with anti-LFAl and anti-CD2 was performed according to the same schedule as the first transplant, because no antimouse antibodies were found. Engraftment was documented on day 31 following the second transplantation. On day 37, skin eruption and diarrhea were observed. As for the other two patients, three skin biopsies were performed. Acute GVHD was documented both on skin and large bowel biopsies. Immunophenotypic analysis of skin biopsies showed very few Langherans cells, a strong expression of DR on keratinocytes, and a lymphocytic infiltration made up of 80% CD4 positive cells. The patient then received an association of steroids (2 mg/kg/d and CsA, 3 mg/kg/d IV). Skin and gut lesions improved transiently, but ultimately flared, and the patient died with severe gut GVHD on day 89 after the second transplant.
Expansion of T lymphocytes from skin biopsy. Skin specimens were washed at least five times in RPM1 containing 10% pooled human sera, 1% L-glutamine (2 mmol/L), and 50 pg/mL gentamycin and then cultured in a 24-well plate (Nunclon, Copenhagen, Denmark) in the same medium supplemented with recombinant IL-2 (rIL-2, 150 BRMP U/mL). Cultures were kept at 37°C in a 5% COz atmosphere. In the four cases presented, T-cell proliferation started as early as 3 days after initiation of the culture. At day 5, to generate a panel of clones from each skin biopsy-derived T-cell line, one responder T cell was seeded in every three culture wells in 96-microwell round bottom culture plates together with pooled allogeneic feeder cells (5 X 104 peripheral blood lymphocytes (PBL) and 5 x lo3 B lymphoblastoid cell line (BLCL), 30 gray irradiated) in the presence of leukoagglutinin-A ( l pg/mL) (Pharmacia, Uppsala, Sweden), and rIL-2 (150 BRMP U/mL). Under these conditions, where 100% T cells are stimulated, maximal cloning efficiency is obtained (as assessed by limiting dilution analysis: frequency of proliferation about 50% to 100%). These conditions were chosen to avoid in vitro antigenic selection, while maintaining as closely as possible the best representation of T cells that grew under rIL-2 alone during the initial culture period. Before specificity assays, the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
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clones were cultured without stimulation in IL-2 alone for at least 2 weeks.
Southern blot analysis. Filter hybridization: after digestion with EcoRI or Hind 111, 15 pg of genomic DNA samples were sizedfractionated by electrophoresis through 1% agarose gels. Southern blotting was performed using a vacuum blotting system (LKB-Pharmacia, St. Quentin en Yvelines, France) on Hybond N+ filters (Amersham, Les Ullis, France) according to suppliers instructions. Hybridization, washing, and autoradiography were performed as previously describedI4 with "P multiprimed probes. Probes: The Jy probe, PH60, containing the 700-bp Hind 111 EcoRI fragment from M13H60, includes the J y l segment.ls.16 This fragment cross-hybridizes with Jy2, but not with JP, JPI, or JP2. The CD probe IBlOBBl corresponds to the C o l fragment and cross-hybridizes with C@"
Polymerase chain reaction (PCR) and sequencing. They were performed essentially as de~cribed.".'~ Briefly, total RNA was isolated from each clone and TCR-a or -p cDNA was obtained, by reverse transcription, using specific C a or C@ antisense primers, respectively. TCR-a and -p cDNA amplifications were done by PCR with sense V-family specific primers and the above mentioned C primer. Different sets of Va/Ca and VB/CD-derived oligonucleotides were used as sense/antisense primers to perform asymetric PCR on each strand of the PCR-amplified cDNA, so that an excess of single stranded DNA of a chosen strand was produced. These second (internal) sets matched to sequences located 3' and 5'. respectively, from those of the V and C primers used for the first amplification. Direct sequencing of amplified DNA strands was performed with sequenase (Amersham, Buckinghamhire, UK) following the manufacturer's instructions and using the corresponding V-and C-internal oligonucleotides as primers for sequencing the minus and the positive strand, respectively. Exceptionally, PCR amplified products were cloned in the pCR-Script vector (Stratagene GMBH, Heidelberg, Germany) following the manufacturer's instructions. Positive colonies were sequenced by using T3 and T7 primers.
Proliferation assay. Resting T cells (2.5 to 5 X IO4), taken more than 2 weeks after the last stimulation, were cocultured for 48 to 72 hours with the indicated irradiated (30 Gy) BLCL in 96-microwell flat-bottomed culture plates at a 1: 1 responder-to-stimulator ratio. Six hours before harvesting, 1 pCi of ('H)thymidine was added to each well, and ('H)thymidine uptake was then measured in a liquid scintillation counter. Results are expressed as the mean of triplicate or quadruplicate cultures. Host BLCL were obtained by coculturing of PBL with Epstein-Barr virus (EBV)-containing supernatant from the virus-producing B95.8 cell line in the presence of 1 pglmL CsA. The following MoAbs were used for specificity studies: anti-DPDR (2D6), -DP (B7.21), -DQ (1A3 or Leu-10).
cytotoxic assay. Cytotoxic activity was tested using a standard Cr release assay already described:" briefly, target cells were labeled with 100 pCi 5'Cr for 2 hours at 37°C. washed three times, and plated at the indicated effector-to-target ratio in a 96-well roundbottom plate. After 4 hours of incubation at 37"C, 100 pL of supernatant from each well was removed and counted in a gamma scintillation counter. Each test was performed in triplicate. Results are expressed as percentage of lysis, according to the following formula: (experimental release -spontaneous release)/(maximal releasespontaneous release) X 100, where experimental release represents mean counts per minute released from the target cells and maximum release from target incubated with 1% cetavlon.
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RESULTS
Obtaining cell lines and cloning. T cells were recovered after culturing skin biopsies in the presence of IL-2 alone and were then cloned by limiting dilution under conditions that trigger the growth of virtually all T cells present in the culture (see Materials and Methods section and Fig 1) . This procedure should select most in vivo activated T cells during the first culture step and during the second step, should allow recovery of virtually all T cells amplified during the first step. In the four cases studied, T cells began to exude from biopsies within 3 days after initiation of the culture. Occurrence of GVHD was confirmed for each case by histopathological analyses. We never obtained skin biopsy-derived Tcell lines when the diagnosis of GVHD was not confirmed; this has also been observed by others."
Clonal diversity of the lines obtained. Partial analysis of the UPNl line has been reported in a previous study ( Table  2 )." Of 34 T-cell clones analyzed in that study, 11 were found to be different. They were then tested for their capacity to recognize mismatched HLA-alleles of the graft. Such capacity was found for three of the l l clones characterized: two CD4+ clones (A4 and D2) recognized HLA-DP101 and one CD8+ clone (TM15) recognized HLA-A2, two of the mismatched HLA-alleles in the GVHD direction (see Tables  1 and 2 ). For this study, 30 more UPN1-derived clones were analyzed and no new type of clone detected (data not shown). Two biopsies were studied for patient UPN2 (UPN2-a and UPN2-b). One was performed 3 days and the other 8 days after onset of GVHD. T cells from UPN2-a were cloned as described in the Materials and Methods section, and CD4+ and CD8+ T-cell clones were analyzed separately. Analysis of TCRy gene rearrangement status of the 21 CD4+ clones indicated that all of them had the same rearrangement pattern and thus were probably derived from a single original T-cell clone, clone HER-l in Table 2 (data not shown). All CD8' T cells were recognized by an anti-TCR-Vpl2 antibody. Moreover, a single junctional sequence was obtained from these cells (Table 3) . Taken together, these results suggest that only two different clones compose the UPN2-a cell line, clones HER-l and -3. From the second biopsy (UPNZb), we derived 38 T-cell clones (26 CD4+ and 12 CD8'). All the CD8' clones shared the same rearrangement and thus were probably derived from a single original clone (HER-30, Fig 2) . Three different rearrangements were found for the CD4+ T-cell clones, suggesting that they derived from three original clones (HER-27, -28, -29). These three CD4+ T-cell clones from the second biopsy were all distinct from the single CD4+ T-cell clone HER-l derived from the first biopsy, as indicated in Fig 3. All T-cell clones obtained from the UPN3 line were CD4'. Seven different TCRy gene rearrangement patterns were found within the 24 T-cell clones whose TCRy gene rearrangement status was determined (Fig 4 shows the 12 first clones analyzed) .
Analysis of the specijicity of the clones obtained. The donor-host pairs are indicated in Table 1 . Patient UPN3 received two grafts, the first from his mother and the second from his father. All the clones obtained were HLA-A29 and came from the second donor (not shown). Clone specificities were determined in a classical manner using MoAbs and BLCL lines from the 1987 New York Workshop panel. Results from representative experiments are shown in Fig 5. T-cell clones, PI, P3, P6, P7, and P10 proliferated strongly when cocultured with the irradiated BLCL BOL, but not against BLCL RSH, VAV, TON, or BTB (for extensive HLA-typing of hosts, donors, and BLCL, see proliferation was blocked by an anti-HLA-DQ (1A3) MoAb, P1 1 was T75, whose recognition was specifically blocked but not by MoAb against HLA-DR (2D6) or HLA-DP (B7-by the HLA-DP specific MoAb B7-21, confirming that this 21). Consequently, these clones were probably specific for clone recognized HLA-DP1301 on T75. Finally, clone P14 HLA-DQ8. The only BLCL recognized by the T-cell clone proliferated only when cocultured with the BLCL JBlO and its proliferation was specifically blocked by MoAb against HLA-DR, thus confirming that P14 probably recognized the HLA-DR402. HLA-DQ8, -DR0402 and -DP1301 were all mismatches of the graft in the GVHD direction. Specificity analysis of the CD4+ T-cell clones HER-27, HER-28, and HER-29 is shown in Fig 6. Clone HER-27 proliferated against BSM and BOL, but not against JHAF or BTB, HER-29 proliferated against BSM and BOL but not against RSH or BTB (again, see Table 1 for extensive HLA typing). Proliferation of both clones was blocked by a HLA-DQ-specific MoAb, but not by HLA-DP or -DR-specific MoAbs. These results suggested that HER-27 and HER-29 T-cell clones were specific for HLA-DQS. Clone HER-28 proliferated against BTB and BOL, but not against BSM or RSH, and this proliferation was blocked by the HLA-DP-specific MoAb B7-21 and not by MoAb against HLA-DR or -DQ. Consequently, this clone probably recognized HLA-DP401. Finally, with respect to the two CDS+ clones HER-3 (from the first biopsy, UPN2-a) and HER-30 (from the second biopsy, UPN2-b) whose specificity analysis is shown in Fig  7, data from both proliferation and cytotoxicity assays demonstrated recognition of the two HLA-B27+ BLCL (BTB and WT24) only. HLA-B27, HLA-DQ8, and HLA-DP401 were all mismatched HLA-alleles in the GVHD direction in this donorhecipient combination. Analysis of the cytotoxic capacity of the above CD4' Tcell clones was not presented in detail, but their cytotoxic potentials are indicated in Table 2 . For all T-cell clones having a cytotoxic potential, their pattern of reactivity always confirmed their specificity, usually tested through proliferation assays.
Diversity of the TCR used. TCR-Va and -Vg chain sequences of selected clones are presented in Table 3 . They confirm the individuality of each clone, as previously deduced from the Southern blot analysis. Most importantly, though the number of clones was low, marked heterogeneity Fig 2) . The CD4+ clone HER-l (derived from the UPN2-a biopsy) was compared with the CD4' clones HER-27, HER-28, and HER-29 derived from the UPN2-b biopsy. These four distinct T-cell clones were detected after Southern blot analysis of 21 different colonies from the UPN2-a and 26 from the UPN2-b biopsies, respectively (not shown).
For of the TCR expressed could be demonstrated. Particularly informative were the sequences of the TCR expressed by the anti-DQ8 specific clones derived from patient UPN3. Thus, although PI and P10 used the same VO6.7-Jpl. 1 rearrangement, the corresponding CDR3 regions were completely different. Furthermore, T-cell clones P3 and W used different VO-JP combination, Vp7-Jpl.2 and Vp5-Jp2.5, respectively. Altogether, these four T-cell clones, although derived from the same patient and having the same specificity within the same tissue, used four different TCR-Va and three different TCR-V@ chains.
DISCUSSION
Since the initial analysis of the parameters critical for the development of GVHD,'.' other factors than the possibility of the graft to mount an allogeneic reaction against the host have been recognized as important in the pathogenesis and clinical outcome of this disease. The preparative regimen, the host response, the presence of microbacterial pathogens and the viral status, have all been evoked and extensively studied.24 A GVHD-like syndrome has also been observed in some autologous situations.' Nevertheless, acute GVHD remains primarily a T-cell mediated disease, which occurs early after BMT and with the immunological peculiarity of being tissue-specific. Very few studies focusing on the characterization of T-cell reactivity at a site of GVHD lesions have been rep~rted.~~.~'-*' This is perhaps because of conclusions drawn from initial studies suggesting that the majority of T cells in allografts lack allo-antigen specificity.2R"'2 Thus, the initial cellular events leading to GVHD are still poorly For personal use only. on September 14, 2017. by guest www.bloodjournal.org From . .
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direction (see Table l ).
ANTIDODIES
understood. Here we report on the functional and structural characterization of skin infiltrating T cells during early GVHD. The objective of the present study was to obtain a sufficient number of host-specific clones to analyze both the diversity of their potential targets and the diversity of the TCRs involved in their recognition. We studied four skin biopsy-derived cell lines obtained from three patients who developed an acute GVHD after allogeneic BMT from HLA mismatched related donors. Our results, summarized in Table 2 , demonstrated (1) that these cell lines were markedly oligoclonal, (2) that a majority of skin biopsy-derived T-cell clones were reactive against host-HLA, and (3) that these T-cell clones used highly diverse TCR, even though they recognized the same HLA specificity within the same tissue. Obviously, the general impact of these results relies on a demonstration that the T cells studied were actually involved in the pathological process. Evidence in support of this assumption, which is necessarily indirect because of the constraints linked to human studies, is as follows: first, our culture conditions should allow growth of clones that are representative of the activated (ie, E-2-receptor positive) T cells infiltrating the biopsy. In this respect, Heidecke et a 1 3 3 elegantly demonstrated that IL-2-receptor positive graft infiltrating cells, but not the IL-2-receptor negative cells were alloreactive effectors on adoptive transfer in syngeneic hosts. Second, T-cell clones characterized in the present work exuded from the biopsies and started to grow actively within 3 days after initiation of the culture. In contrast, we never obtained cell lines when GVHD was not confirmed, strongly suggesting a correlation between the clinical outcome and the obtention of a T-cell line from these biopsies. Along this line, our results are comparable with several other studies, either after kidney, BMT, or heart2'.26.34 transplantation.
Third, a majority of the clones derived from these biopsies are specific for host antigens, although they were obtained without in vitro antigenic selection. Although we cannot formally prove that the clones presented here would have reproduced the clinical manifestations that are characteristics of GVHD, we think we can reasonably infer from our results, as well as from the literature, that the host HLA-specific Tcell clones described in this paper actively took part in the initiation of the GVHD process.
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The next comment to be made concerns the cell lines oligoclonality. After Southern blot analysis of the TCR gene rearrangements of 146 clones obtained under limiting dilution of the cells exuding from the biopsies, we found only 25 distinct T-cell clones (1 l , 2,4, and 8 from the four biopsies, respectively, see Table 2 ). In a regular T-cell cloning assay, it takes more than 10 days for a clone to become macroscopically detectable. Consequently, the fact that we obtained within 5 days a detectable amplification of T-cell lines composed of 2, 4, 8, and 11 clones implies that these clones were both overrepresented and activated in situ. Naturally, this does not necessarily mean that these clones were the only T cells present in the biopsy. Particularly, in view of other works where an important diversity of TCR-Va! and TCR-VP gene transcripts was detected in the skin at the time of acute GVHD,3'.36 our results are also in full agreement with the recent report by R. Leibnitz et al,37 who studied the reactivity of murine hybridomas derived from T cells activated in vivo during GVHD and who suggested that early in the course of the disease, a high percentage of activated T cells sequestered in host spleen or liver were allospecific.
Although the presence of histoincompatible tissue antigens between donor and recipient is the main prerequisite for the development of GVHD, there remains the possibility that allogeneic T cells are not the only cells responsible for the appearance of the disease. Donor TCR-aP T cells can also recognize pathogens, autologous determinants, or allogeneic fragments indirectly, ie, presented by self MHC molecules. If such a recognition had occurred in the situation we have studied, the T cells involved should have been activated, and consequently our culture conditions should have favored them as well as those directed at classical MHC alloantigens. We cannot exclude from our data that such cells were present among the eight T-cell clones derived from UPNl for which we could not document antihost reactivity. In contrast, all clones from the three other biopsies were specific for mismatched HLA-alleles of the graft (see Tables 1 and 2 ). The in vivo relevance of indirect recognition during an allo-antigenic response is a matter of debate. Although the precise nature of the peptides presented together with the host HLA-molecules is presently unknown, indirect recognition can be excluded from our data: for example, clone P1 recognized only HLA-DQ8 bearing BLCL, and this reactivity was specifically blocked by an anti-DQ MoAb with no possible indirect presentation of an HLA-DQ8 peptide within another DQ-allele, which should have been matched with the host, ie, DQ2 in the present case. The same reasoning holds for the other clones, and therefore mismatched HLA-alleles were probably recognized in a direct, rather than an indirect, manner in the cases presented.
Although the high frequency of alloreactive T cells suggests the expression of a broad spectrum of TCRs by these effectors, evidence for restricted TCR-V gene usage by alloreactive T cells has been recently p r~v i d e d . " .~~-~~ Such observations raised the possibility that the immune response leading to graft rejection or acute GVHD could be prevented by selective depletion of alloreactive T cells. Indeed in the case of GVHD, two factors might have contributed to the restricted response: first, acute GVHD occurs rapidly after BMT, when T-cell reconstitution is not yet complete, and second, GVHD lesions affect mainly epithelia, which implies that only part of the allo-repertoire may be involved in this process. Our data demonstrate that this is not the case between HLA mismatched related donors. The best example comes from the analysis of the four DQ8 clones from patient UNP-3, whose TCR was made up of four distinct TCR-V regions combinations.
In conclusion our data provide evidence that in the early stages of acute GVHD after allogeneic BMT, activated T cells at the site of GVHD lesions are host-specific and could potentially recognize any mismatch. Moreover, this T-cell response appears at the same time oligoclonal and clearly not TCR-V region restricted. In the context of an allogeneic graft between HLA mismatched related donors, it is clear that T cells responsible for GVHD cannot be discriminated by the use of any particular TCR-V chain. Therefore, the potential usefulness of TCR-V specific MoAbs as immunotherapeutic agents for the selective elimination of particular TCR-V bearing cells is questionable.
